Drug evaluation review: Dupilumab in atopic dermatitis

Immunotherapy

Volumn 7, Issue 10, 2015, Pages 1043-1058

  Hamilton, Jennifer D ^a   Ungar, Benjamin ^b,c   Guttman Yassky, Emma ^b,c  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

atopic dermatitis; dupilumab; efficacy; eotaxin 3; IL 13; IL 4; IL 4R ; safety; TARC; Th2

Indexed keywords

DUPILUMAB; INTERLEUKIN 13; INTERLEUKIN 4; PLACEBO; ANTIPRURITIC AGENT; CORTICOSTEROID; CYTOKINE; MONOCLONAL ANTIBODY;

ATOPIC DERMATITIS; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; INJECTION SITE REACTION; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RHINOPHARYNGITIS; SKIN INFECTION; TH2 CELL; UPPER RESPIRATORY TRACT INFECTION; ADULT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DERMATITIS, ATOPIC; DRUG SCREENING; IMMUNOLOGY; PRURITUS;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTIPRURITICS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DERMATITIS, ATOPIC; DRUG EVALUATION; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; PRURITUS; TH2 CELLS;

EID: 84971619891     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.69     Document Type: Review

References (82)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatovener. (Stockholm). 60(Suppl. 92), 44-47 (1980).
2. Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. Dermatitis 18(2), 82-91 (2007).
3. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J. Allergy Clin. Immunol. 124(6), 1251-1258 (2009).
4. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based survey. J. Allergy Clin. Immunol. 132(5), 1132-1138 (2013).
5. Margolis DJ, Aptar AJ, Gupta J et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J. Allergy Clin. Immunol. 130(4), 912-917 (2012).
6. Asher MI, Montefort S, Björkstén B et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional studies. Lancet 368(9537), 733-743 (2006).
7. Bingefors K, Svensson Å, Isacson D, Lindberg M. Self-reported lifetime prevalence of atopic dermatitis and co-morbidity with asthma and eczema in adulthood: a population-based crosssectional study. Acta Derm. Venereol. 93(4), 438-441 (2013).
8. Pesce G, Marcon A, Carosso A et al. Adult eczema in Italy: prevalence and associations with environmental factors. J. Eur. Acad. Dermatol. Venereol. 29(6), 1180-1187 (2015).
9. Bannister MJ, Freeman S. Adult-onset atopic dermatitis. Aust. J. Dermatol. 41(4), 225-228 (2000).
10. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 101(3), E8 (1998).
11. Kapoor R, Menon C, Hoffstad O, Bilker W, Leclerc P, Margolis DJ. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J. Am. Acad. Dermatol. 58(1), 68-73 (2008).
12. Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J. Clin. Cell Immunol. 5(2), 202 (2014).
13. Ricci G, Patrizi A, Baldi E, Menna G, Tabanelli M, Masi M. Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J. Am. Acad. Dermatol. 55(5), 765-771 (2006).
14. Dalgard FJ, Gieler U, Tomas-Aragones L et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J. Investig. Dermatol. 135(4), 984-991 (2015).
15. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in atopic dermatitis. J. Allergy Clin. Immunol. 131(2), 428-433 (2013).
16. Wittkowski A, Richards HL, Griffiths CE, Main CJ. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J. Psychosom. Res. 57(2), 195-200 (2004).
17. Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J. Allergy Clin. Immunol. 111(3), 598-602 (2003).
18. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J. Allergy Clin. Immunol. 134(4), 769-779 (2014).
19. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J. Allergy Clin. Immunol. 135(2), 324-336 (2015).
20. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 73(2), 311-318 (2015).
21. Eichenfield LF, Tom WL, Berger TG et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 71(1), 116-132 (2014).
22. Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J. Eur. Acad. Dermatol. Venereol. 26(8), 1045-1060 (2012).
23. Denby KS, Beck LA. Update on systemic therapies for atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 12(4), 421-426 (2012).
24. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-tosevere atopic dermatitis: a systematic review. J. Allergy Clin. Immunol. 133(2), 429-438 (2014).
25. Katayama I, Kohno Y, Akiyama K et al. Japanese guidelines for atopic dermatitis 2014. Allergol. Int. 63(3), 377-398 (2014).
26. Sidbury R, Davis DM, Cohen DE et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J. Am. Acad. Dermatol. 71(2), 327-349 (2014).
27. Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J. Eur. Acad. Dermatol. Venereol. 26(9), 1176-1193 (2012).
28. Gittler JK, Shemer A, Suárez-Fariñas M et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J. Allergy Clin. Immunol. 130(6), 1344-1354 (2012).
29. Kou K, Aihara M, Matsunaga T et al. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. Arch. Dermatol. Res. 304(4), 305-312 (2012).
30. Kim BS, Wang K, Siracusa MC et al. Basophils promote innate lymphoid cell responses in inflamed skin. J. Immunol. 193(7), 3717-3725 (2014).
31. Kakinuma T, Nakamura K, Wakaguwa M et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J. Allergy Clin. Immunol. 107(3), 535-541 (2001).
32. Hijnen D, De Bruin-Weller M, Oosting B et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are diseasespecific markers for atopic dermatitis. J. Allergy Clin. Immunol. 113(2), 334-340 (2004).
33. Suárez-Fariñas M, Dhingra N, Gittler J et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J. Allergy Clin. Immunol. 132(2), 361-370 (2013).
34. Kou K, Okawa T, Yamaguchi Y et al. Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis. Br. J. Dermatol. 171(2), 283-291 (2014).
35. Kagami S, Kakinuma T, Saeki H et al. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/ CCL24, in patients with atopic dermatitis: serum eotaxin-3/ CCL26 levels reflect the disease activity of atopic dermatitis. Clin. Exp. Immunol. 134(2), 309-313 (2003).
36. Kagami S, Saeki H, Komine M et al. Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells. Clin. Exp. Immunol. 141(3), 459-466 (2005).
37. Howell MD, Kim BE, Gao P et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J. Allergy Clin. Immunol. 120(1), 150-155 (2007).
38. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin. Immunol. 126(3), 332-337 (2008).
39. Kaesler S, Volz T, Skabytska Y et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. J. Allergy Clin. Immunol. 134(1), 92-99 (2014).
40. Danso MO, van Drongelen V, Mulder A et al. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipid in human skin equivalents. J. Invest. Dermatol. 134(7), 1941-1950 (2014).
41. Bernard FX, Morel F, Camu M et al. Keratinocytes under fire of proinflammatory cytokines: bona fide innate immune cells involved in the physiopathology of chronic atopic dermatitis and psoriasis. J. Allergy (Cairo). 2012, 718725 (2012).
42. Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol. Allergy Clin. North Am. 30(3), 309-321 (2010).
43. Park HY, Kim CR, Huh IS et al. Staphylococcus aureus colonization in acute and chronic skin lesions of patients with atopic dermatitis. Ann. Dermatol. 25(4), 410-416 (2013).
44. Czarnowicki T, Gonzalez J, Shemer A et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J. Allergy Clin. Immunol. 136(1), 104-115 (2015).
45. Czarnowicki T, Malajian D, Shemer A et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. J. Allergy Clin. Immunol. 136(1), 208-211 (2015).
46. Nograles KE, Zaba LC, Shemer A et al. IL-22 producing "T22" T cells account for up-regulated IL-22 in atopic dermatitis despite reduced IL-17 producing TH17 T cells. J. Allergy Clin. Immunol. 123(6), 1244-1252 (2009).
47. Suárez-Fariñas M, Ungar B, Correa da Rosa J et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J. Allergy Clin. Immunol. 135(5), 1218-1227 (2015).
48. Thepen T, Langeveld-Wildschut EG, Bihari IC et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J. Allergy Clin. Immunol. 97(3), 828-837 (1996).
49. Akdis CA, Akdis M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin. Exp. Allergy 33(12), 1618-1621 (2003).
50. Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wüthrich B. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 56(9), 841-849 (2001).
51. Beck LA, Thaçi D, Hamilton JD et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 371(2), 130-139 (2014).
52. Umeshita-Suyama R, Sugimoto R, Akaiwa M et al. Characterization of IL-4 and IL-13 signals dependent on the human IL-13 receptor α chain 1: redundancy of requirement of tyrosine residue for STAT3 activation. Int. Immunol. 12(11), 1499-1509 (2000).
53. Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci. Signal. 1(51), pe55 (2015).
54. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebocontrolled and double blind pilot study. J. Dtsch. Dermatol. Ges. 8(12), 990-998 (2010).
55. Fernández-Antón Martínez MC, Alfageme Roldán F, Ciudad Blanco C, Suárez Fernández R. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 105(3), 312-323 (2014).
56. Oldhoff JM, Darsow U, Werfel T et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60(5), 693-696 (2005).
57. Stelara®. Prescribing information, revised 03/2014. Janssen Biotech, Inc., PA, USA (2014). www.stelarainfo.com/pdf/PrescribingInformation.pdf
58. Stelara 45 mg solution for injection. Summary of product characteristics, last updated 23/12/2014. Janssen Biologics B.V., Leiden, The Netherlands. www.ema.europa.eu/docs/en-GB/document-library
59. Xolair®. Prescribing information, revised 9/2014. Genentech, Inc., CA, USA (2014). www.gene.com/download/pdf/xolair-prescribing.pdf
60. Xolair (75 mg powder and solvent for solution for injection). Summary of product characteristics, last updated 14/04/2015. Novartis Europharm Limited, Camberley, UK. www.ema.europa.eu/docs/en-GB/document-library
61. Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368(26), 2455-2466 (2013).
62. Wenzel S, Wang L, Pirozzi G et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthma with baseline eosinophil levels above and below 300 cells/μL. Am. J. Respir. Crit. Care Med. 191, B19, Abstract 68982 (2015).
63. Bachert C, Mannent L, Naclerio RM et al. Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma. Allergy 70(Suppl. 101), 107-112 (2015).
64. ClinicalTrials Database: NCT02379052. https://clinicaltrials.gov/ct2/show/NCT02379052
65. Tintle S, Shemer A, Suárez-Fariñas M et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J. Allergy Clin. Immunol. 128(3), 583-593 (2011).
66. Suárez-Fariñas M, Gittler JK, Shemer A, Cardinale I, Kreuger JG, Guttman-Yassky E. Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. J. Allergy Clin. Immunol. 131(2), 577-579 (2013).
67. Kimura T, Sugaya M, Suga H et al. Variations in serum TARC and I-TAC levels reflect minor changes in disease activity and pruritus in atopic dermatitis. Acta. Derm. Venereol. 94(3), 331-332 (2014).
68. Khattri S, Shemer A, Rozenblit M et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J. Allergy Clin. Immunol. 133(6), 1626-1634 (2014).
69. Hamilton JD, Suárez-Fariñas M, Dhingra N et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 134(6), 1293-1300 (2014).
70. Thaçi D, Simpson EL, Beck LA et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis (AD) inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging Phase 2b trial. Lancet doi:10.1016/S0140-6736(15)00388-8 (2015) (Epub ahead of print).
71. Simpson E, Worm M, Soong W et al. Dupilumab improves patient-reported outcomes (PROs) in a Phase 2 study in adults with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 135(Suppl.), AB167, Abstract 544 (2015).
72. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp. Dermatol. 10(1), 11-18 (2001).
73. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br. J. Dermatol. 162(3), 587-593 (2010).
74. Phan NQ, Blome C, Fritz F et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta. Derm. Venereol. 92(5), 502-507 (2012).
75. Jenkins HH, Spencer ED, Weissgerber AJ, Osborne LA, Pellegrini JE. Correlating an 11-point verbal numeric rating scale to a 4-point verbal rating scale in the measurement of pruritis. J. Perianesth. Nurs. 24(3), 152-155 (2009).
76. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb J. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 195(1), 10-19 (1997).
77. Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch. Dermatol. 140(12), 1513-1519 (2004).
78. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19(3), 210-216 (1994).
79. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67(6), 361-370 (1983).
80. Suárez-Fariñas M, Tintle SJ, Shemer A et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J. Allergy Clin. Immunol. 127(4), 954-964 (2011).
81. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J. Allergy Clin. Immunol. 124(6), 1235-1244 (2009).
82. Hamilton J, Hamon S, Chaudhry U et al. Dupilumab suppression of Th2 biomarkers correlates with a reduction in transepidermal water loss (TEWL) and clinical improvements in adults with moderate-to-severe atopic dermatitis (AD). J. Investig. Dermatol. 135(Suppl. 1s), S29, Abstract 169 (2015).